A guideline approach to therapy step-down utilising Flutiform(R): change and step-down (FFLU-X study)
Phase of Trial: Phase IV
Latest Information Update: 03 Apr 2017
Price : $35 *
At a glance
- Drugs Formoterol/fluticasone propionate (Primary) ; Salmeterol/fluticasone propionate
- Indications Asthma
- Focus Therapeutic Use
- Acronyms FFLU-X study
- Sponsors Napp Pharmaceutical Group
- 31 Aug 2018 Biomarkers information updated
- 05 Apr 2016 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 21 Oct 2015 Planned End Date changed from 1 Sep 2015 to 1 Mar 2016 as reported by ClinicalTrials.gov.